

Updates in Triple-Negative Breast Cancer: Expanding Horizons and Optimizing Outcomes

Recorded Podcast

References:

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70(1):7–30.
2. American Cancer Society. Breast Cancer: Facts & Figures 2019-2020. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf>. Published 2019. Accessed August 17, 2020.
3. Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. *Mod Pathol*. 2011;24(2):157–67.
4. Mehanna J, Haddad FG, Eid R, et al. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. *Int J Womens Health*. 2019;11:431–7.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version July 2020.
6. Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med*. 2017;376(22):2147–59.
7. Trodelvy (sacituzumab govitecan-hziy) [prescribing information]. Morris Plains, NJ: Immunomedics, Inc.; 2020.
8. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. *N Engl J Med*. 2019;380(8):741–51.
9. Schmid P, Adams S, Rugo HS, et al; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*. 2018;379(22):2108–21.
10. Schmid P, Adams S, Rugo HS, et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). *J Clin Oncol*. 2019;37(15_suppl):1003.
11. Tanya E. Keenan, MD, MPH and Sara M. Tolaney, MD, MPH. Role of Immunotherapy in Triple-Negative Breast Cancer. *J Natl Compr Canc Netw* 2020;18(4):479–489.
12. Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. *J Clin Oncol*. 2017;35(15_suppl):abstract 506.
13. Schmid P, Cortes J, Dent R, et al. KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs placebo as adjuvant therapy for triple negative breast cancer (TNBC). *Ann Oncol*. 2019;30(suppl_5):v851-v934.
14. S. National Library of Medicine. NCT 02926196: Adjuvant Treatment for High Risk Triple Negative Breast Cancer Patients with Anti-PD-L1 Antibody Avelumab (A-Brave). <https://clinicaltrials.gov/>. Accessed October 15, 2018.

15. Puztai L, Barlow WE, Ganz PA, et al. SWOG S1418/NRG-BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy. *Cancer Res.* 2018;78(4 Suppl):abstract OT1-02-04.
16. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. *Ann Oncol.* 2019;30(4):558–66.
17. Cortes J, Guo Z, Karantza V, Aktan G. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC). *J Clin Oncol.* 2018;36(5_Suppl):abstract TPS18.
18. Domchek SM, Postel-Vinay S, Im SA, et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Presented at San Antonio Breast Cancer Symposium; December 5-7, 2018; San Antonio, TX. Abstract PD5-04.
19. Mitri ZI, Vuky J, Kemmer KA, et al. A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer. *J Clin Oncol.* 2019;37(15_Suppl):abstract TPS1111.
20. Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. *JAMA Oncol.* 2019;5(8):1132-40.
21. Voorwerk L, Slagter M, Hurlings H, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. *Nat Med.* 2019;25(6):920-8.
22. Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med.* 2017;377(6):523–33.
23. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med.* 2018;379(8):753–63.